METXF
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, whic… Read more
METXF (METXF) - Net Assets
Latest net assets as of November 2025: $1.33 Million USD
Based on the latest financial reports, METXF (METXF) has net assets worth $1.33 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.55 Million) and total liabilities ($220.66K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.33 Million |
| % of Total Assets | 85.79% |
| Annual Growth Rate | 60.63% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 76.87 |
METXF - Net Assets Trend (2022–2025)
This chart illustrates how METXF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for METXF (2022–2025)
The table below shows the annual net assets of METXF from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $1.50 Million | +1.85% |
| 2024-08-31 | $1.48 Million | +181.96% |
| 2023-08-31 | $523.39K | +44.37% |
| 2022-08-31 | $362.54K | -- |
Equity Component Analysis
This analysis shows how different components contribute to METXF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 967124200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $11.23 Million | 747.24% |
| Total Equity | $1.50 Million | 100.00% |
METXF Competitors by Market Cap
The table below lists competitors of METXF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Windsor Machines Limited
NSE:WINDMACHIN
|
$49.55 Million |
|
Jin Air Co Ltd
KO:272450
|
$49.55 Million |
|
Nitratos de Chile SA
SN:NITRATOS
|
$49.57 Million |
|
BABYTREE GROUP
F:BTR
|
$49.60 Million |
|
Tecogen Inc.
NYSE:TGEN
|
$49.52 Million |
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
$49.52 Million |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
$49.51 Million |
|
YASHO INDUSTRIES ORD (BSE)
NSE:YASHO
|
$49.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in METXF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,475,727 to 1,503,101, a change of 27,374 (1.9%).
- Net loss of 1,193,200 reduced equity.
- Other factors increased equity by 1,220,574.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.19 Million | -79.38% |
| Other Changes | $1.22 Million | +81.2% |
| Total Change | $- | 1.85% |
Book Value vs Market Value Analysis
This analysis compares METXF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 58.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 191.55x to 58.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-08-31 | $0.02 | $2.95 | x |
| 2023-08-31 | $0.02 | $2.95 | x |
| 2024-08-31 | $0.06 | $2.95 | x |
| 2025-08-31 | $0.05 | $2.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently METXF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -79.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-79.38%) is above the historical average (-581.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -911.55% | 0.00% | 0.00x | 1.10x | $-3.34 Million |
| 2023 | -1245.80% | 0.00% | 0.00x | 1.28x | $-6.57 Million |
| 2024 | -87.73% | 0.00% | 0.00x | 1.04x | $-1.44 Million |
| 2025 | -79.38% | 0.00% | 0.00x | 1.17x | $-1.34 Million |
Industry Comparison
This section compares METXF's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| METXF (METXF) | $1.33 Million | -911.55% | 0.17x | $49.53 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |